Plain-English translation of NCT07240194 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether combining three medications — , a , and — can help treat aggressive lymphomas that have either come back after remission or stopped responding to standard treatments. The trial focuses on patients who have a specific genetic change (called a TP53 aberration) that makes their cancer harder to treat. Researchers hope this three-drug combination will work better than existing options for this difficult-to-treat group.
People with this type of lymphoma and this genetic change have poor outcomes and limited options because their cancers resist standard treatments. This medication combination has not been tested together in this patient group before, so researchers want to see if it can offer hope for patients who have run out of other choices.
You likely qualify if…
You likely don't qualify if…
You would receive the three-medication combination during treatment cycles, with the first dose of one medication () given on Day 1 to prepare your body. Throughout the study, you'll have regular check-ins with doctors, blood tests, and imaging scans to monitor how you're responding and to watch for any side effects. The study will follow you closely to track whether the treatment helps shrink your lymphoma and to measure how long any benefits last.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China